Change of Adviser

19 June 2019

AorTech International plc

("AorTech" or "the Company")

Change of Adviser

AorTech (AIM: AOR) announces the appointment of Shore Capital and Corporate Limited as its Nominated Adviser and Shore Capital Stockbrokers Limited as Broker, with immediate effect. This follows the acquisition of Stockdale Securities Limited by Shore Capital Markets Limited.

Further information please contact:

AorTech International plc Tel: +44 (0)7730 718 296

Bill Brown, Chairman

Shore Capital (Nominated Adviser and Broker) Tel: +44 (0) 20 7601 6120

Tom Griffiths / David Coaten

About AorTech:

AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA and Japanese Ministry of Health approvals. 

Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.

In addition to the licensing of biostable polymers, AorTech is now developing medical devices utilising the key properties of its world class polymers.